PROK PROKIDNEY CORP. Insider Trading

Director Pereira sells entire stake of 757,162 shares across 4 transactions for $1.9M as PROK faces $-16.5M annual loss and 53.5% stock decline from highs.

Brian JG Pereira, a director at ProKidney Corp., executed a complete liquidation of his equity position through 4 separate sales totaling 757,162 shares for $1,884,577.38 across November 12-13, 2025, reducing his holdings from 757,162 shares to 0 shares (-100.0%). The sales occurred at prices between $2.37 and $2.72 per share, against a current price of $2.41 and a 52-week high of $5.18. This exit occurs in the context of severe operational headwinds: the company posted net income of $-16,469,000.00 on minimal revenue of $217,000.00 in its latest quarter, and reported negative full-year earnings. The complete divestiture of the director's equity stake—rather than a partial or gradual reduction—coincides with the stock trading 53.5% below its 52-week peak and down 24.0% over the prior 30 days, suggesting the director has no remaining financial alignment with future company performance.

10% owner Control Empresarial de Capitales buys 387,393 shares at $0.71 as stock down -76.4% from 52-week high

Control Empresarial de Capitales, holding 73.84M shares (73,842,723 shares) post-transaction, purchased 387,393 shares at $0.71 on 2025-04-22, increasing its stake by approximately 0.5% relative to pre-transaction holdings of 73.46M shares. The buy occurs as PROK trades at $0.99, down -76.4% from its 52-week high of $4.20 and -42.4% over 90 days. The insider's cross-ticker track record shows 20 prior buys with an average 30-day return of -19.7%, a negative pattern. At PROK specifically, the insider has executed 5 consecutive buys between 2025-04-11 and 2025-04-22 with outcomes not yet measurable. Company fundamentals are challenged: net income was negative at $-17,910,000.00 ($-17.9M) over the most recent full fiscal year, indicating the company was unprofitable.

10% owner Control Empresarial de Capitales bought 25,000 shares of PROK at $0.75 on 2025-04-17; stock down 82.6% from 52-week high, company unprofitable.

Control Empresarial de Capitales, a 10% shareholder, purchased 25,000 shares at $0.75 on 2025-04-17, increasing holdings from 73.43M to 73.46M shares. The purchase occurred as PROKIDNEY's stock trades at $0.73, down 82.6% from its 52-week high of $4.20 and down 24.0% over the prior 30 days. The company reported a net loss of $17.9M for its most recent full fiscal year. This marks the fifth consecutive buy by this insider at PROK within a seven-day window (2025-04-10 through 2025-04-17), suggesting sustained accumulation during a period of severe price decline, though measurable outcomes from these recent trades are not yet available.

10% owner Control Empresarial de Capitales buys 100,000 shares of PROK at $0.75; stock down 81.2% from 52-week high.

Control Empresarial de Capitales purchased 100,000 shares at $0.75 on 2025-04-16, adding to holdings now at 73,430,330 shares. The purchase occurs in the context of severe stock deterioration: PROK is trading at $0.79 current price, down 81.2% from its 52-week high of $4.20, and has declined 18.5% over the prior 30 days and 52.4% over 90 days. The company reported net income of $-17,910,000.00, indicating ongoing losses. The insider's cross-ticker track record shows 20 prior buys with an average 30-day return of -12.4%, and at this ticker specifically, the prior 5 purchases (all within the same 7-day window in mid-April 2025) have outcomes not yet measurable. The repetitive pattern of purchases over consecutive days in a depressed, unprofitable stock warrants monitoring of whether this signals material changes in company prospects or reflects continued accumulation despite deteriorating fundamentals.

10% owner Control Empresarial bought 736.1K shares at blended avg $0.71 across 2 txns (Apr 14-15); stock down 81% from $4.20 high, PROK unprofitable at -$17.9M NI.

Control Empresarial de Capitales S.A. de C.V. filed two separate purchases totaling 736,105 shares for $520,599.41, bringing holdings to 73.33M shares. The 10% owner acquired shares at a blended average price of $0.71, which is below the current price of $0.80 but far above the 52-week high of $4.20 — the stock is down 81.0% from its peak and down 23.1% over the past 30 days. PROK reported a net loss of $17,910,000.00 for its most recent full fiscal year, making the company unprofitable. The insider's prior buy-track record across all tickers shows an average 30-day return of -11.6%, and none of his prior PROK trades have measurable 90-day outcomes yet given their recent timing (April 10, 11, and 16).

10% owner Control Empresarial bought 1,034,118 shares (1.03M) at $0.61 in 2 transactions; stock down 82.4% from 52-week high and company unprofitable

Control Empresarial de Capitales executed 2 separate purchases totaling 1,034,118 shares for $628,847.16 ($628.8K) at $0.61 per share on 2025-04-10 and 2025-04-11, increasing its stake from 71,560,107 to 72,594,225 shares. The purchases occurred as PROKIDNEY's stock is down 82.4% from its 52-week high of $4.20 and down 53.2% over the 90-day period, while the company reported a full-year net loss of $17,910,000.00. The 10% shareholder's cross-ticker history shows an average 30-day return of -12.5% on 20 prior open-market buys, and PROKIDNEY itself had 1 prior measured trade with outcome data not yet available (filed 2025-04-14). These purchases represent a modest 1.4% increase in the insider's holdings at a price substantially below the 52-week high, against a backdrop of significant share price deterioration and confirmed unprofitability.

10% Owner Control Empresarial buys 8,264,462 shares for $19,999,998.04 at $2.42; holds 71,560,107 post-trade.

Control Empresarial de Capitales S.A. de C.V., a 10% shareholder, deployed $19,999,998.04 to acquire 8,264,462 shares at $2.42 on 2024-06-11, increasing holdings by 13.1% to 71,560,107 shares. This was the insider's third open-market purchase at PROK; the two prior buys at this ticker (2024-03-25 and 2024-03-22) each posted 90-day gains (89.3% and 74.6% respectively), and across a broader cross-ticker history, the insider's 20 prior buys averaged 78.8% 90-day returns with a 100% win rate. However, PROK's fundamentals deteriorated significantly: the company posted a net loss of $9,492,000 in its most recent fiscal year, and the stock has declined 83.0% from its 52-week high of $13.08 and 33.8% in the past 30 days. The $2.23 current price (only -8.0% below the transaction price at $2.42) occurs in the context of a profoundly weakened balance sheet, distinguishing this accumulation from the prior two buys at this ticker which occurred before material deterioration.

Director Legorreta buys 22,617,909 shares of PROK for $54.7M; stock down 79.1% from 52-wk high, company unprofitable.

Legorreta Pablo G., a Director, purchased 22,617,909 shares for $54,735,339.78, establishing a new position after holding zero shares pre-transaction. The timing is notable: PROKIDNEY CORP trades at $2.73, down 79.1% from its 52-week high of $13.08, and the stock has fallen 30.4% over the past 30 days despite a 93.6% gain over 90 days. The company reported a net loss of $9,492,000 over its most recent full fiscal year, indicating ongoing operating challenges. Legorreta's historical cross-ticker insider trading record shows 6 prior buys with a 0.00% 90-day win rate and an average 90-day return of -10.1%, suggesting his open-market purchases have not preceded price appreciation. This substantial new commitment by a director into a loss-making company at a deeply depressed valuation demands scrutiny regarding his motivation and information access.